Drug Trial Radar · NCT04150029
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
90
Actual
Start
Sep 1, 2020
Primary completion
Oct 25, 2024
Study completion Oct 25, 2024
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
Conditions
- Acute Myeloid Leukemia
Interventions
MBG453Drug
Solution for intravenous infusion
VenetoclaxDrug
Tablet for oral administration
AzacitidineDrug
Solution for subcutaneous injection or intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities (DLT)(Safety run-in Patients Only)Time frame: From Cycle 1 Day 8 to end of Cycle 2; Cycle =28 Days
- Percentage of Participants Achieving Complete Remission (CR) (CR Rate)Time frame: approx. 31 months
Locations
28 sites in 10 countries. Site status is shown where the registry gives one.
25Uni of Alabama at Birmingham
Birmingham, Alabama
Yale University School Of Medicine
New Haven, Connecticut
Uni Of Iowa Hospitals And Clinics
Iowa City, Iowa
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic Rochester
Rochester, Minnesota
Memorial Sloan Kettering
New York, New York
Weill Cornell Medicine NY-Presb
New York, New York
Levine Cancer Insitute Carolinas Healthcare System
Charlotte, North Carolina
Duke Univ Medical Center
Durham, North Carolina
Chattanooga Onc And Hem Assoc PC
Chattanooga, Tennessee
MD Anderson Cancer Center University of Texas
Houston, Texas
Huntsman Cancer Institute Univ of Utah
Salt Lake City, Utah
Novartis Investigative Site
Clayton, Victoria, Australia
Novartis Investigative Site
Vancouver, British Columbia, Canada
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Leipzig, Saxony, Germany
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Fukushima, Fukushima, Japan
Novartis Investigative Site
Yamagata, Yamagata, Japan
Novartis Investigative Site
Seoul, Seocho gu, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Kaohsiung City, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.